CY1113071T1 - Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα - Google Patents
Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεαInfo
- Publication number
- CY1113071T1 CY1113071T1 CY20121100765T CY121100765T CY1113071T1 CY 1113071 T1 CY1113071 T1 CY 1113071T1 CY 20121100765 T CY20121100765 T CY 20121100765T CY 121100765 T CY121100765 T CY 121100765T CY 1113071 T1 CY1113071 T1 CY 1113071T1
- Authority
- CY
- Cyprus
- Prior art keywords
- optional
- competitor
- kappa
- competitive
- schizophrenia
- Prior art date
Links
- 230000002860 competitive effect Effects 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 | |
| EP09703808A EP2252581B1 (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113071T1 true CY1113071T1 (el) | 2016-04-13 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100765T CY1113071T1 (el) | 2008-01-22 | 2012-08-24 | Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7709522B2 (OSRAM) |
| EP (1) | EP2252581B1 (OSRAM) |
| JP (1) | JP5345637B2 (OSRAM) |
| KR (1) | KR101172170B1 (OSRAM) |
| CN (1) | CN101925576B (OSRAM) |
| AR (1) | AR070158A1 (OSRAM) |
| AU (1) | AU2009206653B2 (OSRAM) |
| BR (1) | BRPI0907382B8 (OSRAM) |
| CA (1) | CA2713025C (OSRAM) |
| CO (1) | CO6290644A2 (OSRAM) |
| CY (1) | CY1113071T1 (OSRAM) |
| DK (1) | DK2252581T3 (OSRAM) |
| DO (1) | DOP2010000222A (OSRAM) |
| EA (1) | EA017484B1 (OSRAM) |
| EC (1) | ECSP10010365A (OSRAM) |
| ES (1) | ES2388708T3 (OSRAM) |
| HR (1) | HRP20120558T1 (OSRAM) |
| IL (1) | IL206038A (OSRAM) |
| JO (1) | JO2797B1 (OSRAM) |
| MA (1) | MA32751B1 (OSRAM) |
| MX (1) | MX2010007849A (OSRAM) |
| MY (1) | MY163014A (OSRAM) |
| NZ (1) | NZ586225A (OSRAM) |
| PE (1) | PE20091317A1 (OSRAM) |
| PL (1) | PL2252581T3 (OSRAM) |
| PT (1) | PT2252581E (OSRAM) |
| SI (1) | SI2252581T1 (OSRAM) |
| TN (1) | TN2010000306A1 (OSRAM) |
| TW (1) | TWI422369B (OSRAM) |
| UA (1) | UA100715C2 (OSRAM) |
| WO (1) | WO2009094260A1 (OSRAM) |
| ZA (1) | ZA201003908B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907230A2 (pt) * | 2008-01-22 | 2019-09-24 | Takeda Pharmaceuticals Co | composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto |
| CN101925576B (zh) * | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
| EP2757881A4 (en) | 2011-09-15 | 2014-11-12 | Univ Kansas | KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF |
| US10813925B2 (en) | 2011-09-19 | 2020-10-27 | Carmel—Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| CA2858752C (en) | 2011-12-09 | 2019-12-31 | Research Triangle Institute | 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| JP2016519161A (ja) * | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| EP4574210A3 (en) | 2017-03-17 | 2025-10-15 | The Scripps Research Institute | Kappa opioid receptor antagonists and products and methods related thereto |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| IL308221A (en) | 2021-05-04 | 2024-01-01 | Janssen Pharmaceuticals Inc | Preparations and methods for treating depression |
| IL314179A (en) * | 2022-01-10 | 2024-09-01 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
| US20250064779A1 (en) * | 2022-01-10 | 2025-02-27 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN119156210A (zh) * | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 纯形式的结晶阿替卡普兰 |
| EP4489730A1 (en) * | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| JP2025508051A (ja) | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) * | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| JP3706307B2 (ja) * | 1999-05-12 | 2005-10-12 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾジアゼピン誘導体 |
| WO2002029418A1 (en) * | 2000-10-05 | 2002-04-11 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| US6528518B2 (en) * | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| US7119196B2 (en) * | 2002-03-28 | 2006-10-10 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| ES2392200T3 (es) * | 2002-09-19 | 2012-12-05 | Eli Lilly & Company | Ésteres de diarilo como antagonistas del receptor opiáceo |
| DE602004016127D1 (de) * | 2003-03-07 | 2008-10-09 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| AU2004220112A1 (en) | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| BRPI0417156A (pt) * | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
| JP2007516284A (ja) * | 2003-12-22 | 2007-06-21 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| CA2559207A1 (en) * | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| DE602005022572D1 (de) * | 2004-03-12 | 2010-09-09 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| ATE399164T1 (de) * | 2004-03-12 | 2008-07-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| ES2318472T3 (es) * | 2004-03-15 | 2009-05-01 | Eli Lilly And Company | Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad. |
| EP1735268B1 (en) * | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| DK2001456T3 (da) | 2006-04-04 | 2010-04-12 | Emodys Gmbh | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
| JP2010500372A (ja) | 2006-08-09 | 2010-01-07 | スミスクライン ビーチャム コーポレーション | オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物 |
| CN101522614B (zh) | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| KR20090051778A (ko) | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| CN101925576B (zh) * | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
-
2009
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113071T1 (el) | Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα | |
| ATE496051T1 (de) | Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten | |
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| CY1119102T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεισαυτων | |
| ATE505467T1 (de) | 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten | |
| DE602007007323D1 (de) | Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor | |
| EA201100306A1 (ru) | Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1 | |
| BRPI0922384A2 (pt) | "manipulador de suprimento para equipamento". | |
| ATE489389T1 (de) | 2 -heteroaryl- pyrrolo ä3, 4-cüpyrrol- derivate und deren verwendung als scd inhibitoren | |
| CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
| UA95768C2 (ru) | Антагонисты мускариновых рецепторов ацетилхолина | |
| BRPI0922224A2 (pt) | composições de inibidores de proteína tirosina quiinase receptora. | |
| ATE526325T1 (de) | Substituierte benzimidazole als kinaseinhibitoren | |
| DE602007004999D1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten | |
| FR2935906B1 (fr) | Dispositif de reeducation perineale. | |
| IT1392499B1 (it) | Dispositivo di rilevamento dell'impatto. | |
| ATE481405T1 (de) | Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| BRPI0814772A2 (pt) | Indazóis substituídos por 5-piridinona | |
| UY32331A (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| EP2349624A4 (en) | PORTABLE ELECTROERODER | |
| NI200900081U (es) | Anticuerpos agonistas de trkb y sus usos. | |
| CO6260091A2 (es) | Derivados de iminopiridina y su uso | |
| FR2944041B1 (fr) | Plateforme en encorbellement equipee d'un dispositif d'extension. | |
| UA107684C2 (xx) | АГОНІСТИ РЕЦЕПТОРА mGlu2 |